Gossamer Bio (GOSS) Projected to Post Earnings on Tuesday

Key Points

• Gossamer Bio is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.18) per share and revenues of $4.12 million for the quarter.
• The company recently reported a narrower loss of ($0.16) EPS, exceeding expectations, and had a revenue of $9.89 million, significantly above estimates.
• Several analysts have issued positive ratings for Gossamer Bio, with Goldman Sachs raising its price target from $7.00 to $8.00, reflecting growing confidence in the company's potential.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect Gossamer Bio to post earnings of ($0.18) per share and revenue of $4.12 million for the quarter.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.17) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. The firm had revenue of $11.49 million for the quarter, compared to analysts' expectations of $4.12 million. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 344.81%. On average, analysts expect Gossamer Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gossamer Bio Stock Up 1.1%

Shares of GOSS traded up $0.02 during trading hours on Friday, hitting $1.76. The company had a trading volume of 3,069,886 shares, compared to its average volume of 1,936,289. Gossamer Bio has a 52-week low of $0.66 and a 52-week high of $2.23. The firm has a fifty day moving average price of $1.50 and a 200-day moving average price of $1.23. The stock has a market capitalization of $400.05 million, a price-to-earnings ratio of -2.84 and a beta of 1.96. The company has a debt-to-equity ratio of 6.70, a quick ratio of 5.71 and a current ratio of 4.40.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on GOSS shares. Scotiabank assumed coverage on shares of Gossamer Bio in a research report on Monday, July 14th. They set a "sector outperform" rating and a $11.00 price target for the company. Wedbush lifted their target price on Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, The Goldman Sachs Group upped their price target on Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a report on Friday, May 16th.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its position in Gossamer Bio by 100.4% during the second quarter. Geode Capital Management LLC now owns 4,555,080 shares of the company's stock valued at $5,604,000 after acquiring an additional 2,282,632 shares during the last quarter. Focus Partners Wealth bought a new stake in shares of Gossamer Bio during the 1st quarter valued at about $770,000. Jane Street Group LLC increased its position in shares of Gossamer Bio by 5,250.1% during the 1st quarter. Jane Street Group LLC now owns 683,423 shares of the company's stock valued at $752,000 after purchasing an additional 670,649 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Gossamer Bio by 720.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company's stock worth $1,034,000 after purchasing an additional 825,047 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Gossamer Bio in the first quarter worth approximately $213,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.